electroCore FY2026 EPS Estimate Increased by HC Wainwright

electroCore, Inc. (NASDAQ:ECOR) – Equities researchers at HC Wainwright increased their FY2026 earnings estimates for electroCore in a note issued to investors on Wednesday, December 18th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.52 for the year, up from their prior estimate of $0.43. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for electroCore’s current full-year earnings is ($1.49) per share. HC Wainwright also issued estimates for electroCore’s FY2027 earnings at $1.34 EPS and FY2028 earnings at $2.24 EPS.

electroCore Price Performance

NASDAQ ECOR opened at $14.52 on Thursday. The firm’s fifty day moving average price is $11.51 and its 200 day moving average price is $8.12. electroCore has a 12 month low of $5.25 and a 12 month high of $17.84. The company has a market capitalization of $95.18 million, a price-to-earnings ratio of -7.93 and a beta of 0.57.

Hedge Funds Weigh In On electroCore

Hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its holdings in shares of electroCore by 3.4% in the 2nd quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock valued at $442,000 after purchasing an additional 2,270 shares during the last quarter. Geode Capital Management LLC lifted its stake in electroCore by 10.3% in the third quarter. Geode Capital Management LLC now owns 63,485 shares of the company’s stock valued at $458,000 after buying an additional 5,951 shares during the last quarter. International Assets Investment Management LLC lifted its stake in electroCore by 27.9% in the second quarter. International Assets Investment Management LLC now owns 67,820 shares of the company’s stock valued at $436,000 after buying an additional 14,800 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new stake in shares of electroCore in the third quarter valued at approximately $255,000. Hedge funds and other institutional investors own 26.74% of the company’s stock.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.